Citadel Advisors
TPST icon

Citadel Advisors’s Tempest Therapeutics TPST Stock Holding History

Citadel Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,185
Closed -$21K – 15115
2025
Q1 		$21K Sell
2,185
-469
-18% -$5.32K ﹤0.01% 13107
2024
Q4 		$28.8K Buy
2,654
+539
+25% +$6.96K ﹤0.01% 12912
2024
Q3 		$38.5K Sell
2,115
-162
-7% -$3.32K ﹤0.01% 12178
2024
Q2 		$64.8K Buy
2,277
+1,239
+119% +$53.6K ﹤0.01% 11468
2024
Q1 		$52.8K Buy
1,038
+992
+2,157% +$50.1K ﹤0.01% 12129
2023
Q4 		$2.64K Buy
+46
New +$2.18K ﹤0.01% 13674
2021
Q2 		– Sell
-264
Closed -$62K – 14446
2021
Q1 		$62K Buy
+264
New +$107K ﹤0.01% 12796
2020
Q3 		– Sell
-98
Closed -$34K – 10741
2020
Q2 		$34K Buy
+98
New +$39.1K ﹤0.01% 9431
2017
Q2 		– Sell
-4
Closed -$21K – 8071
2017
Q1 		$21K Buy
+4
New +$18.6K ﹤0.01% 7235
2015
Q4 		– Sell
-5
Closed -$121K – 9203
2015
Q3 		$121K Buy
5
+4
+400% +$269K ﹤0.01% 6773
2015
Q2 		$69K Sell
1
-1
-50% -$91.6K ﹤0.01% 7430
2015
Q1 		$167K Buy
+2
New +$266K ﹤0.01% 6366

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's TPST Position: Q3 2024 in Review

Citadel Advisors sold out of Tempest Therapeutics (TPST) in Q3 2024, closing a stake of 7,095 shares — an estimated $145K sold.

Citadel Advisors first reported a position in TPST in Q1 2015 and held it in 16 quarters. The position peaked at $9.95M in Q1 2015. 28 funds tracked by Wall St. Rank hold TPST as of Q3 2024.

  • Citadel Advisors reported no remaining Tempest Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 7,095 Tempest Therapeutics shares in Q3 2024, an estimated $145K.
  • Citadel Advisors first reported a position in Tempest Therapeutics in Q1 2015 and held it in 16 quarters.
  • Citadel Advisors's Tempest Therapeutics position peaked at $9.95M in Q1 2015.
  • 28 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.